Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—a market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling ...

(Reuters) -U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental ...

The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still walk. A pause on shipments to older, non-ambulatory patients remains in ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now. Earlier on June 4, Sarepta Therapeutics announced that the US FDA has granted Platform Technology ...

Sarepta Therapeutics Inc. has refused to pause all shipments of its Elevidys treatment after three deaths were linked to the company’s gene therapies, the Food and Drug Administration said Friday.

Sarepta's stock tumbled over 40% to $12.81, its lowest level in more than nine years, after being briefly halted. A company spokesperson said the drugmaker has yet to receive a formal request.

Investing.com - Mizuho has reiterated an Outperform rating and $40.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) stock, citing reduced concerns about potential FDA market withdrawal of ...

After the FDA request, Cambridge, Massachusetts-based Sarepta said in a statement that it will continue to ship the therapy to ambulatory people but maintain a halt it implemented June 15 for ...

(Bloomberg) -- Sarepta Therapeutics Inc. has refused to pause all shipments of its Elevidys treatment after three deaths were linked to the company’s gene therapies, the Food and Drug Administration ...

Sarepta says it won’t comply with FDA request to stop shipping gene therapy Elevidys Stock Markets Published 07/18/2025, 03:18 PM Updated 07/18/2025, 09:35 PM ...